Sleep lab better than home testing for apnoea:
This article was originally published in Clinica
Investigation of obstructive sleep apnoea syndrome in a sleep laboratory is associated with a better outcome than recording cardiorespiratory variables at home, a US computer modelling study has found. Reporting their findings in the March issue of Annals of Internal Medicine, Dr Ronald Chervin and colleagues say that under almost all the situations investigated in the study, laboratory-based polysomnography provided maximal quality-adjusted life-years in the five years immediately after the initial diagnostic evaluation. However, an editorial in the same journal criticises the study for including only one type of home testing device and for assuming that all patients need to undergo the same diagnostic tests.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.